8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 23, 2007

SCHERING–PLOUGH CORPORATION

(Exact Name of Registrant as Specified in its Charter)

New Jersey
(State or Other Jurisdiction of
Incorporation) 1-6571
(Commission File Number) 22-1918501
(IRS Employer
Identification Number)

2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (908) 298-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

Schering-Plough today issued a press release titled “Schering-Plough Reports Financial Results for Second Quarter of 2007” and provided additional supplemental financial data. The press release is furnished as Exhibit 99.1 to this 8-K. The supplemental financial data is furnished as Exhibit 99.2 to this 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

99.1 Press release dated July 23, 2007 titled “Schering-Plough Reports Financial Results for Second Quarter of 2007”

99.2 Supplemental Financial Data

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation

By: /s/ Steven H. Koehler Steven H. Koehler

Vice President and Controller

Date: July 23, 2007

Exhibit Index

Exhibit Number	Description
99.1	Press release dated July 23, 2007 titled “Schering-Plough Reports Financial Results for Second Quarter of 2007”
99.2	Supplemental Financial Data

EX-99.1

Exhibit 99.1

FOR RELEASE: IMMEDIATELY	Media Contact:	Steve Galpin, Jr.
		(908) 298-7415
	Investor Contact:	Alex Kelly
		(908) 298-7436

SCHERING-PLOUGH REPORTS FINANCIAL RESULTS
FOR SECOND QUARTER OF 2007

Company Continues Strong Performance in Second Quarter of 2007,
Prepares for Integration of Organon BioSciences

KENILWORTH, N.J., July 23, 2007 – Schering-Plough Corporation (NYSE: SGP) today reported financial results for the second quarter of 2007 and commented on its planned acquisition of Organon BioSciences N.V. (OBS) including its Organon human health business and Intervet animal health business, as announced March 12, 2007.

          “Schering-Plough’s second quarter performance shows clearly that we have sustained our momentum,” said Fred Hassan, chairman and CEO. “Our strategy to grow the top line is succeeding – we have now recorded our 11^th consecutive quarter of double-digit adjusted sales growth. Our strong top-line growth combined with financial discipline have produced superior EPS growth. We are advancing and expanding our research pipeline. And we look forward to adding Organon BioSciences to our company.”

          For the 2007 second quarter, Schering-Plough reported net income available to common shareholders of $517 million or 34 cents per common share on a GAAP basis. The results include charges of $106 million or 7 cents per share related to a $60 million upfront licensing payment and $46 million in items related to the planned OBS acquisition. Excluding those charges, earnings per share for the 2007 second quarter would have been 41 cents (see table below). For the 2006 second quarter, Schering-Plough reported net income of $237 million or 16 cents per common share on a GAAP basis. Excluding charges of $138 million or 9 cents per share related to actions to streamline Schering-Plough’s manufacturing operations as announced June 1, 2006 (see table below), Schering-Plough’s income in the 2006 second quarter would have been $375 million or 25 cents per share.

          GAAP net sales for the 2007 second quarter totaled $3.2 billion, up 13 percent versus the 2006 second quarter. Including an adjustment of an assumed 50 percent of global cholesterol joint venture net sales (see table below), Schering-Plough’s adjusted net sales (hereinafter referred to as “adjusted sales”) for the 2007 second quarter would have totaled $3.8 billion, a 15 percent increase compared to $3.3 billion on a similar adjusted basis in the 2006 second quarter. Schering-Plough does not record

 - 2 - 

sales of its cholesterol joint venture with Merck & Co., Inc. (Merck), as the venture is accounted for under the equity method.

          On the planned OBS acquisition, the company noted that the transaction remains subject to certain closing conditions, including regulatory approvals. Hassan said, “We are making steady progress and continue to expect to close by year-end. We are moving carefully and deliberately to ensure that we execute this transaction the right way – to build strength and value for the long term.”

          He added, “We are excited about the opportunities created by Organon in gynecology, fertility, anesthesia and neuroscience. In animal health, we see great potential in bringing together our product lines with those of Intervet.” Schering-Plough’s late-stage research pipeline will also be significantly strengthened with the addition of five Phase III compounds from Organon.

          “Overall, this combination offers a strong strategic fit, a strong scientific fit, and a strong financial fit. It’s about becoming a company with greater balance in our businesses and an exciting and productive pipeline. As we prepare to complete this transaction, we are also being careful not to get distracted, knowing that sustaining the momentum in our business and research operations continues to be a top priority.”

          Reviewing second quarter results, Hassan emphasized, “We’re growing across a broad front. Seven out of our 10 largest-selling products, including VYTORIN and ZETIA, posted double-digit sales growth for the quarter,” he said. “And even with the recent arrival of multi-source U.S. generic competition, our cholesterol franchise continues to be dynamic. In fact, VYTORIN and ZETIA are the only major cholesterol-lowering brands to have grown U.S. market share in 2007.” The strategy to expand Schering-Plough’s geographic presence is paying off, with higher sales in emerging markets. Also contributing to second quarter results were solid performances from the company’s Animal Health and Consumer Health Care businesses.

          R&D remains a critical investment area for Schering-Plough as a research-based pharmaceutical company. “We are investing in internal innovation,” said Hassan, “and we are bringing in external innovation. Together, they will be the engine that drives our future growth.”

          Internally generated compounds include four that have been designated “fast-track” by the U.S. Food and Drug Administration, a status granted to compounds with the potential to address serious unmet medical needs.

     Foremost among external initiatives is the planned acquisition of Organon and Intervet. In addition, the company recently entered into three agreements, including two for Phase III compounds, with:

• Novacea, Inc., to develop and commercialize Asentar, a Phase III compound in development for treating androgen-independent prostate cancer;

- 3 -

• PeriCor Pharmaceuticals, for worldwide rights to acadesine, a Phase III development project for preventing ischemia-reperfusion injury, a life-threatening cardiac surgery complication; and

• AVEO Pharmaceuticals, to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor, which has demonstrated efficacy in preclinical models of human cancer.

            Commenting on Schering-Plough, Hassan said: “Today, we are at an exciting time for our company, for the colleagues with us now and those who will be joining us. The OBS acquisition will be an important step in the Build the Base phase of our Action Agenda. Our company has stayed the course with its six- to eight-year road map and our employees remain focused and engaged in shaping our future. Together with Organon and Intervet, we will become a stronger company, able to do more – for our customers, for our stakeholders and for the patients who are counting on us. Together, we will work to sustain the momentum of our businesses and deliver high performance for the long term.”

Second Quarter 2007 Results

For the 2007 second quarter, Schering-Plough reported net income available to common shareholders of $517 million or 34 cents per common share on a GAAP basis. The results include charges of $106 million or 7 cents per share related to a $60 million upfront licensing payment and $46 million in acquisition-related costs (consisting of a $35 million mark-to-market loss on a Euro-denominated currency option and integration planning costs of $11 million). Excluding those charges, earnings per share for the 2007 second quarter would have been 41 cents. For the 2006 second quarter, Schering-Plough reported net income of $237 million or 16 cents per common share on a GAAP basis. Excluding charges of $138 million or 9 cents per share related to actions to streamline Schering-Plough’s manufacturing operations, Schering-Plough’s income in the 2006 second quarter would have been $375 million or 25 cents per share.

          GAAP net sales for the 2007 second quarter totaled $3.2 billion, up 13 percent as compared to the second quarter of 2006. The sales growth versus 2006 reflects a 3 percent favorable impact from foreign exchange.

          Global cholesterol joint venture net sales, which include VYTORIN and ZETIA, totaled $1.2 billion in the 2007 second quarter, a 30 percent increase compared to net sales of $958 million in the comparable 2006 period. Schering-Plough does not record sales of its cholesterol joint venture with Merck as the venture is accounted for under the equity method. Including an adjustment of an assumed 50 percent of the global cholesterol joint venture net sales, Schering-Plough’s adjusted sales for the 2007 second quarter would have been $3.8 billion, a 15 percent increase, compared to $3.3 billion on a similar adjusted basis in the 2006 second quarter.

- 4 -

     Overall, Schering-Plough shares in approximately 50 percent of the profits of the joint venture with Merck, although there are different profit-sharing arrangements for the cholesterol products in countries around the world. Schering-Plough records its share of the income from operations in “Equity income from cholesterol joint venture,” which totaled $490 million in the 2007 second quarter versus $355 million in the second quarter of 2006. Schering-Plough noted that it incurs substantial costs such as selling, general and administrative costs that are not reflected in “Equity income from cholesterol joint venture” and are borne by its overall cost structure. There is a separate co-marketing agreement with Bayer for ZETIA in Japan, where the product was launched in June 2007.

     Sales of REMICADE increased 28 percent to $394 million in the second quarter of 2007 due to continued market growth and expanded use across indications. REMICADE is a treatment for immune-mediated inflammatory disorders that Schering-Plough markets in countries outside the United States (except in Japan and certain other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, pediatric Crohn’s disease and ulcerative colitis.

     Global sales of NASONEX, an inhaled nasal corticosteroid for allergies, rose 22 percent to $295 million versus the 2006 period, with increased sales in the United States and international markets.

     Sales of PEGINTRON for hepatitis C increased 3 percent to $234 million in the 2007 second quarter due to higher sales in Latin America and Europe, and tempered by lower sales in the United States and Japan.

     Global sales of CLARINEX, a nonsedating antihistamine, in the second quarter of 2007 were $250 million compared to $226 million in the prior period. International sales of prescription CLARITIN were $102 million in the second quarter compared to 2006 sales of $104 million.

     Sales of TEMODAR, a treatment for certain types of brain tumors, grew 26 percent to $216 million due primarily to increased sales in international markets. The growth rate for TEMODAR is expected to moderate as significant penetration in U.S. and EU markets has already been achieved for this product. Also reporting higher sales in the quarter was CAELYX, up 23 percent to $65 million.

     Among other prescription products posting higher sales in the 2007 second quarter was the antibiotic AVELOX, up 30 percent to $75 million, primarily as a result of increased market share.

     Consumer Health Care sales were $394 million in the 2007 second quarter, up 13 percent versus the 2006 period. The increase was primarily due to higher sales of OTC CLARITIN and MiraLAX, which was launched in February 2007 as the first Rx-to-OTC switch in the laxative category in more than 30 years.

- 5 -

          Animal Health sales increased 10 percent to $264 million, reflecting solid growth internationally, led by the poultry, companion animal, aquaculture and swine product lines, coupled with a positive impact from foreign currency exchange rates.

          Schering-Plough incurs substantial costs such as selling, general and administrative costs that are not reflected in “Equity income from cholesterol joint venture” and are borne by the overall cost structure of Schering-Plough. As a result, Schering-Plough’s gross margin and ratios of selling, general and administrative (SG&A) expenses and R&D expenses as a percentage of sales do not reflect the benefit of the impact of the cholesterol joint venture’s operating results.

          Schering-Plough’s gross margin was 69.3 percent for the 2007 second quarter as compared to 64.4 percent in the 2006 period on a GAAP basis. Gross margin in the 2006 second quarter would have been 66.4 percent when excluding $58 million in charges related to actions to streamline Schering-Plough’s manufacturing operations. The gross margin improvement was due primarily to improved product mix and cost savings from the 2006 manufacturing streamlining actions. Additionally, Schering-Plough continues to achieve greater production efficiencies and process improvements through its “Right First Time” initiative.

          SG&A expenses were $1.4 billion in the second quarter of 2007, up 11 percent versus $1.2 billion in the prior year period. SG&A in the second quarter of 2007 increased primarily due to increased promotional spending.

          Research and development spending for the 2007 second quarter increased to $696 million compared to $539 million in the second quarter of 2006. Included in R&D spending in the second quarter of 2007 was $60 million related to an upfront payment made for a licensing transaction (Novacea) that closed in the second quarter. The increase in R&D expenses was also due to higher spending for clinical trials and related activities, and investments to build greater breadth and capacity to support Schering-Plough’s progressing pipeline.

Recent Developments

The company also offered the following summary of recent significant developments that have previously been announced, including:

• Entered into an exclusive worldwide agreement with AVEO Pharmaceuticals to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor in early development. (Announced by AVEO April 4)

• Received a Request for Additional Information from the Federal Trade Commission (FTC) regarding Schering-Plough’s planned acquisition of Organon BioSciences. (Announced May 4)

- 6 -

• Entered into an exclusive worldwide license agreement with Novacea, Inc. for the development and commercialization of Asentar (DN-101). Asentar is a novel, proprietary, high-dose oral formulation of calcitriol. (Announced May 30)

• Reported results from a Phase III study that showed maintenance chemotherapy with CAELYX (pegylated liposomal doxorubicin hydrochloride) significantly prolonged time-to-progression in patients with metastatic breast cancer after first-line chemotherapy. (Announced June 3)

• Announced European Commission approval of a new indication for REMICADE (infliximab) allowing for the treatment of severe, active Crohn’s disease in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy or have contraindications for such therapies. (Announced June 7)

• Announced that ZETIA (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestine, was available in Japan for use in patients with hypercholesterolemia, familial hypercholesterolemia or homozygous sitosterolemia. (Announced June 8)

• Reported on data showing that patients with ankylosing spondylitis who received REMICADE over two years experienced significant improvement in spinal mobility and sustained reductions in spinal inflammation. (Announced June 15)

• Reported on favorable rulings by the U.S. District Court for the District of Massachusetts, which dismissed all claims relating to Schering-Plough’s branded pharmaceutical products in a class action lawsuit involving several pharmaceutical companies and the setting of average wholesale prices for prescription products. (Announced June 21)

• Gained European Commission approval for combination therapy with PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin) for the treatment of previously untreated adult patients with chronic hepatitis C who are coinfected with clinically stable HIV. (Announced June 25)

• Metabasis Therapeutics, Inc. announced Schering-Plough’s intention to terminate the agreements it had entered into with Metabasis and Valeant Pharmaceuticals International for the development and commercialization of pradefovir to treat chronic hepatitis B and to return all rights to the product back to Metabasis. (Announced July 17)

• Announced the worldwide licensing of acadesine from PeriCor Pharmaceuticals. Acadesine is in Phase III clinical development for the prevention of ischemia-reperfusion injury, a life-threatening cardiac surgery complication. (Announced July 19)

- 7 -

Second Quarter 2007 Conference Call and Webcast

Schering-Plough will conduct a conference call today at 8 a.m. (EDT) to review the 2007 second quarter results. To listen live to the call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID #3320866. A replay of the call will be available beginning later on July 23 through 5 p.m. on Aug. 20. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID #3320866. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the “Presentations/Webcasts” link. A replay of the webcast will be available starting on July 23 through 5 p.m. on Aug. 20.

DISCLOSURE NOTICE: The information in this press release, the comments of Schering-Plough officers during the earnings teleconference/webcast on July 23, 2007, beginning at 8 a.m. (EDT), and other written reports and oral statements made from time to time by the company may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and are based on current expectations or forecasts of future events. You can identify these forward-looking statements by their use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “project,” “intend,” “plan,” “potential,” “will,” and other similar words and terms. In particular, forward-looking statements include statements relating to the company’s plans; its strategies; its progress under the Action Agenda and anticipated timing regarding future performance of the Action Agenda; business prospects; anticipated growth; timing and conditions of regulatory approvals and expected synergies related to the Organon BioSciences acquisition; ability to access the capital markets on optimal terms; prospective products or product approvals; trends in performance; anticipated timing of clinical trials and its impact on R&D spending; anticipated exclusivity periods; actions to enhance clinical, R&D, manufacturing and post-marketing systems; and the potential of certain products including VYTORIN and ZETIA. Actual results may vary materially from the company’s forward-looking statements, and there are no guarantees about the performance of Schering-Plough stock or Schering-Plough’s business. Schering-Plough does not assume the obligation to update any forward-looking statement. A number of risks and uncertainties could cause results to differ materially from forward-looking statements, including, among other uncertainties market forces; economic factors such as interest rate and exchange rate fluctuations; obtaining regulatory approvals and satisfaction of other customary closing conditions for the Organon BioSciences acquisition; the outcome of contingencies such as litigation and investigations; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the regulatory process (including product approvals, labeling and post-marketing actions); and scientific developments relating to marketed products or pipeline projects. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough’s Securities and Exchange Commission filings, including Part II, Item 1A, “Risk Factors” in the company’s first quarter 2007 10-Q.

          Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough’s vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

# # #

- 8 -

SCHERING-PLOUGH CORPORATION

Report for the second quarter ended June 30 (unaudited):
(Amounts in millions, except per share figures)

	Second Quarter						Six Months
	2007			2006			2007			2006
Net sales	$	3,178		$	2,818		$	6,153		$	5,369
Cost of sales		977			1,004			1,913			1,897
Selling, general and administrative		1,358			1,224			2,572			2,310
Research and development 1/		696			539			1,403			1,020
Other income, net 2/		(16	)		(19	)		(62	)		(52	)
Special and acquisition related charges 3/		11			80			12			80
Equity income from cholesterol joint venture		(490	)		(355	)		(978	)		(666	)
Income before income taxes		642			345			1,293			780
Income tax expense		103			86			190			172
Net income before cumulative effect of a change in accounting principle	$	539		$	259		$	1,103		$	608
Cumulative effect of a change in accounting principle, net of tax		—			—			—			(22	)
Net income	$	539		$	259		$	1,103		$	630
Preferred stock dividends		22			22			43			43
Net income available to common shareholders	$	517		$	237		$	1,060		$	587
Diluted earnings per common share:
Earnings available to common shareholders before cumulative effect of a change in accounting principle 4/	$	0.34		$	0.16		$	0.70		$	0.38
Cumulative effect of a change in accounting principle, net of tax		—			—			—			0.02
Diluted earnings per common share 4/	$	0.34		$	0.16		$	0.70		$	0.40
Average common shares outstanding – diluted		1,587			1,489			1,579			1,487

The company incurs substantial costs related to the cholesterol joint venture, such as selling, general and administrative costs, that are not reflected in the “Equity income from cholesterol joint venture” and are borne by the overall cost structure of Schering-Plough.
1/	Included in research and development for the three months ended June 30, 2007 is $60 million related to an upfront payment made for licensing of a product. Research and development for the six months ended June 30, 2007 includes $156 million related to upfront payments made for licensing of products.
2/	Included in other income, net for the three and six months ended June 30, 2007 are mark-to-market losses of $35 million and $31 million, respectively, related to a Euro denominated currency option related to the planned acquisition of Organon BioSciences.
3/	Included in special and acquisition related charges for the three and six months ended June 30, 2007 is $11 million and $12 million, respectively, related to the planned acquisition of Organon BioSciences.
4/	Diluted earnings per common share for the three month period ended June 30, 2007 is calculated based on net income of $539 million and average diluted shares outstanding of 1,587. Diluted earnings per common share for the six month period ended June 30, 2007 is calculated based on net income of $1.103 billion and average diluted shares outstanding of 1,579. The increase in average diluted shares outstanding in the three and six months ended June 30, 2007 is due to the preferred shares being dilutive under accounting rules. The preferred shares were not dilutive for the three and six months ended June 30, 2006.

- more -

- 9 -

SCHERING-PLOUGH CORPORATION

Report for the period ended June 30 (unaudited):

GAAP Net Sales by Key Product
(Dollars in millions)

	Second Quarter							Six Months
	2007		2006		%			2007		2006		%
GLOBAL PHARMACEUTICALS	$	2,520	$	2,230		13	%	$	4,918	$	4,263		15	%
REMICADE		394		307		28	%		767		585		31	%
NASONEX		295		242		22	%		579		471		23	%
CLARINEX / AERIUS		250		226		11	%		455		386		18	%
PEGINTRON		234		226		3	%		451		423		7	%
TEMODAR		216		171		26	%		412		334		23	%
CLARITIN RX		102		104		(1	%)		214		205		5	%
INTEGRILIN		78		82		(5	%)		163		162		—
AVELOX		75		58		30	%		191		138		38	%
REBETOL		74		86		(14	%)		146		164		(11	%)
CAELYX		65		53		23	%		127		104		22	%
PROVENTIL / ALBUTEROL CFC		61		63		(4	%)		114		104		10	%
INTRON A		55		64		(13	%)		115		124		(7	%)
SUBUTEX / SUBOXONE		52		53		(2	%)		108		101		7	%
ELOCON		43		38		12	%		79		72		8	%
ASMANEX		42		20		108	%		85		40		112	%
FORADIL		26		23		10	%		52		44		17	%
NOXAFIL		20		3		N/M			36		4		N/M
Other Pharmaceuticals		438		411		7	%		824		802		3	%
CONSUMER HEALTH CARE		394		349		13	%		739		659		12	%
OTC		182		149		22	%		359		302		19	%
OTC CLARITIN		137		111		23	%		264		222		19	%
Foot Care		102		96		7	%		180		179		1	%
Sun Care		110		104		6	%		200		178		12	%
ANIMAL HEALTH		264		239		10	%		496		447		11	%
CONSOLIDATED GAAP NET SALES	$	3,178	$	2,818		13	%	$	6,153	$	5,369		15	%

NOTE: Additional information about U.S. and international sales for specific products is available by calling the company or visiting the Investor Relations Web site at http://ir.schering-plough.com.

- more -

 - 10 - 

SCHERING-PLOUGH CORPORATION

Reconciliation of Non-U.S. GAAP Financial Measures

Adjusted net sales, defined as net sales plus an assumed 50 percent of global cholesterol joint venture net sales.

	Three months ended June 30
(Dollars in millions)	(unaudited)
	2007		2006		%
Net sales, as reported	$	3,178	$	2,818		13	%
50 percent of cholesterol joint venture net sales a/		624		479
Adjusted net sales	$	3,802	$	3,297		15	%

	Six months ended June 30
(Dollars in millions)	(unaudited)
	2007		2006		%
Net sales, as reported	$	6,153	$	5,369		15	%
50 percent of cholesterol joint venture net sales a/		1,199		868
Adjusted net sales	$	7,352	$	6,237		18	%

a/

Total net sales of the cholesterol joint venture for the three months ended June 30, 2007 and 2006 were $1.2 billion and $958 million, respectively. Total net sales of the cholesterol joint venture for the six months ended June 30, 2007 and 2006 were $2.4 billion and $1.7 billion, respectively.

NOTE: Adjusted net sales, defined as net sales plus an assumed 50 percent of global cholesterol joint venture net sales, is a non-U.S. GAAP measure used by management in evaluating the performance of Schering-Plough’s overall business. Schering-Plough believes that this performance measure contributes to a more complete understanding by investors of the overall results of the company. Schering-Plough provides this information to supplement the reader’s understanding of the importance to the company of its share of results from the operations of the cholesterol joint venture. Net sales (excluding the cholesterol joint venture net sales) is required to be presented under U.S. GAAP. The cholesterol joint venture’s net sales are included as a component of income from operations in the calculation of Schering-Plough’s “Equity income from cholesterol joint venture.” Net sales of the cholesterol joint venture do not include net sales of cholesterol products in non-joint venture territories.

 - 11 - 

SCHERING-PLOUGH CORPORATION

Reconciliation of Non-U.S. GAAP Financial Measures

Net income available to common shareholders and diluted earnings per common share, excluding specified items

	Three months ended
	June 30, 2007 (unaudited)
	Net income
	available to
	common		Diluted earnings
(Dollars in millions)	shareholders		per common share
As reported	$	517	$	0.34
Specified items
• Upfront R&D payments		60		0.04
• Acquisition related
Integration planning ($11)
Loss on currency option ($35)
Total acquisition related		46		0.03
Total specified items		106		0.07
Excluding specified items	$	623	$	0.41

NOTE: Net income available to common shareholders and diluted earnings per common share, excluding specified items are non-U.S. GAAP measures used by management in evaluating the performance of Schering-Plough’s overall business. Upfront licensing payments and acquisition related costs have been excluded from net income available to common shareholders as Schering-Plough does not consider these charges to be indicative of continuing operating results. Schering-Plough believes that these performance measures contribute to a more complete understanding by investors of the overall results of the company. Net income available to common shareholders and diluted earnings per common share, as reported, are required to be presented under U.S. GAAP.

 - 12 - 

SCHERING-PLOUGH CORPORATION

Reconciliation of Non-U.S. GAAP Financial Measures

Specified items related to manufacturing changes
Three months ended June 30, 2006 (unaudited)
(Dollars in millions)

	Cost of		Special
Specified items	sales		charges		Total
Accelerated depreciation	$	13	$	—	$	13
Severance		—		25		25
Asset impairments and other		—		55		55
Inventory write-offs		45		—		45
Total specified items related to manufacturing changes	$	58	$	80	$	138

Reconciliation of Non-U.S. GAAP Financial Measures
Three months ended June 30, 2006 (unaudited)
(Dollars in millions, except per share figures)

				Net income		Diluted
	Gross margin			available to common		earnings per
	%			shareholders		share
As reported		64.4	%	$	237	$	0.16
Specified Items related to manufacturing changes		2.0	%		138		0.09
Excluding specified items related to manufacturing changes		66.4	%	$	375	$	0.25

NOTE: Gross margin, net income available to common shareholders and diluted earnings per share excluding specified items related to manufacturing changes are non-U.S. GAAP measures used by management in evaluating the performance of Schering-Plough’s overall business. These specified items have been excluded as Schering-Plough does not consider these charges to be indicative of continuing operating results. Schering-Plough believes that these performance measures contribute to a more complete understanding by investors of the overall results of the company. Gross margin, net income available to common shareholders and diluted earnings per share, as reported, are required to be presented under U.S. GAAP.

# # #

EX-99.2

Exhibit 99.2

SCHERING-PLOUGH CORPORATION
STATEMENTS OF CONSOLIDATED OPERATIONS
(Dollars in Millions, except EPS)
(Unaudited)

	2007												2006
	1st			2nd			3rd	4th	6			Full	1st			2nd			3rd			4th			6			Full			2nd Qtr			6 Mos.
	Qtr.			Qtr.			Qtr.	Qtr.	Mos.			Year	Qtr.			Qtr.			Qtr.			Qtr.			Mos.			Year			vs			vs
	$			$			$	$	$			$	$			$			$			$			$			$			2nd Qtr			6 Mos.
Net sales		2,975			3,178					6,153				2,551			2,818			2,574			2,650			5,369			10,594			13	%		15	%
Cost of sales 1/		937			977					1,913				893			1,004			885			915			1,897			3,697			(3	%)		1	%
Gross profit		2,038			2,201					4,240				1,658			1,814			1,689			1,735			3,472			6,897			21	%		22	%
Selling, general and administrative		1,213			1,358					2,572				1,086			1,224			1,158			1,250			2,310			4,718			11	%		11	%
Research and development 2/		707			696					1,403				481			539			536			631			1,020			2,188			29	%		38	%
Other income, net 3/		(48	)		(16	)				(62	)			(34	)		(19	)		(37	)		(46	)		(52	)		(135	)		(16	%)		19	%
Special and acquisition related charges 4/		1			11					12				—			80			10			12			80			102			*			*
Equity income from cholesterol joint venture		(487	)		(490	)				(978	)			(311	)		(355	)		(390	)		(403	)		(666	)		(1,459	)		38	%		47	%
Income before income taxes		652			642					1,293				436			345			412			291			780			1,483			86	%		66	%
Income tax expense 4/		87			103					190				86			86			103			87			172			362			20	%		10	%
Net income before cumulative effect of a change in accounting principle		565			539					1,103				350			259			309			204			608			1,121			108	%		81	%
Cumulative effect of a change in accounting principle, net of tax		—			—					—				(22	)		—			—			—			(22	)		(22	)		*			*
Net income		565			539					1,103				372			259			309			204			630			1,143			108	%		75	%
Preferred stock dividends		22			22					43				22			22			22			22			43			86			*			*
Net income available to common shareholders		543			517					1,060				350			237			287			182			587			1,057			118	%		80	%
Diluted earnings per common share:
Earnings available to common shareholders before cumulative effect of a change in accounting principle 6/		0.36			0.34					0.70				0.22			0.16			0.19			0.12			0.38			0.69
Cumulative effect of a change in accounting principle, net of tax		—			—					—				0.02			—			—			—			0.02			0.02
Diluted earnings per common share 6/		0.36			0.34					0.70				0.24			0.16			0.19			0.12			0.40			0.71
Avg. shares outstanding- diluted		1,571			1,587					1,579				1,486			1,489			1,492			1,497			1,487			1,491
Actual shares outstanding		1,489			1,496					1,496				1,481			1,481			1,483			1,487			1,481			1,487
Ratios to net sales
Net sales		100.0	%		100.0	%				100.0	%			100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%
Cost of sales		31.5	%		30.7	%				31.1	%			35.0	%		35.6	%		34.4	%		34.5	%		35.3	%		34.9	%
Gross margin		68.5	%		69.3	%				68.9	%			65.0	%		64.4	%		65.6	%		65.5	%		64.7	%		65.1	%
Selling, general and administrative		40.8	%		42.7	%				41.8	%			42.6	%		43.4	%		45.0	%		47.2	%		43.0	%		44.5	%
Research and development		23.8	%		21.9	%				22.8	%			18.8	%		19.1	%		20.8	%		23.8	%		19.0	%		20.6	%
Income before income taxes		21.9	%		20.2	%				21.0	%			17.1	%		12.2	%		16.0	%		11.0	%		15.0	%		14.0	%
Net income		19.0	%		17.0	%				17.9	%			14.6	%		9.2	%		12.0	%		7.7	%		11.8	%		10.8	%

*	Not a meaningful percentage
	Note: The Company incurs substantial costs, such as selling, general and administrative costs, that are not reflected in the “Equity income from cholesterol joint venture” and are borne by the overall cost structure of Schering-Plough.
1/	Included in cost of sales for the three and six months ended June 30, 2006 is $58 million of inventory write-off’s and accelerated depreciation related to the manufacturing changes announced June 1, 2006. Cost of sales for the twelve months ended December 31, 2006 included $146 million of inventory write-offs, accelerated depreciation and other charges related to the manufacturing changes.
2/	Research and development for the three months ended June 30, 2007 includes $60 million related to an upfront payment made for licensing of a product. Research and development for the six months ended June 30, 2007 includes $156 million related to upfront payments made for licensing of products. Included in research and development for the twelve months ended December 31, 2006 is a $15 million payment for licensing of a product.
3/	Included in other income, net for the three and six months ended June 30, 2007 is $35 million and $31 million, respectively, related to a mark-to-market loss on a Euro denominated currency option related to the planned acquisition of Organon BioSciences.
4/	For the three and six months ended June 30, 2007, special and acquisition related charges comprised of integration planning activities related to Organon BioSciences in the amount of $11 million and $12 million, respectively.
	Special and acquisition related charges of $102 million for the twelve months ended December 31, 2006 include severance and fixed asset write-offs related to the manufacturing changes.
5/	Tax expense for all periods presented primarily relates to foreign tax expense as the Company did not recognize the benefit of U.S. tax operating losses.
6/	Diluted earnings per common share for the three month period ended June 30, 2007 is calculated based on net income of $539 million and average diluted shares outstanding of 1,587. Diluted earnings per common share for the six month period ended June 30, 2007 is calculated based on net income of $1.103 billion and average diluted shares outstanding of 1,579. Diluted earnings per common share for the three month period ended March 31, 2007 is calculated based on net income of $565 million and average diluted shares outstanding of 1,571. The increase in average diluted shares outstanding for the three and six month period ended June 30, 2007 and three month period ended March 31, 2007 are due to the preferred shares being dilutive under accounting rules. The preferred shares were not dilutive in 2006.

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 1

SCHERING-PLOUGH CORPORATION
ANALYSIS OF NET SALES AND ADJUSTED NET SALES
(Dollars in Millions)

	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.
Cholesterol Joint Venture:		1,150		1,248				2,397			778		958		1,010		1,082		1,736		3,829		30	%		38	%
U.S.		897		958				1,854			634		784		820		852		1,419		3,091		22	%		31	%
International		253		290				543			144		174		190		230		317		738		68	%		71	%
50% of Cholesterol Joint Venture:		575		624				1,199			389		479		505		541		868		1,915		30	%		38	%
Prescription Pharma:		2,398		2,520				4,918			2,032		2,230		2,087		2,211		4,263		8,561		13	%		15	%
U.S.		802		771				1,573			656		718		733		800		1,375		2,908		7	%		14	%
International		1,596		1,749				3,345			1,376		1,512		1,354		1,411		2,888		5,653		16	%		16	%
Consumer Health Care		345		394				739			311		349		259		205		659		1,123		13	%		12	%
Animal Health:		232		264				496			208		239		228		234		447		910		10	%		11	%
U.S.		58		58				116			57		62		72		50		118		240		(6	%)		(2	%)
International		174		206				380			151		177		156		184		329		670		16	%		15	%
Consolidated GAAP Net Sales:		2,975		3,178				6,153			2,551		2,818		2,574		2,650		5,369		10,594		13	%		15	%
U.S.		1,179		1,195				2,374			999		1,103		1,047		1,043		2,102		4,192		8	%		13	%
International		1,796		1,983				3,779			1,552		1,715		1,527		1,607		3,267		6,402		16	%		16	%
Adjusted Net Sales:		3,550		3,802				7,352			2,940		3,297		3,079		3,191		6,237		12,509		15	%		18	%

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 2

SCHERING-PLOUGH CORPORATION
CHOLESTEROL FRANCHISE NET SALES
(Dollars in Millions)

	2007											2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.
Global Zetia: 1/		544		605				1,149			415		474		501		535		889		1,925		28	%		29	%
U.S.		408		424				832			315		363		389		405		679		1,472		17	%		23	%
International		136		181				317			100		111		112		130		210		453		63	%		51	%
Global Vytorin: 1/		616		683				1,299			371		491		517		554		862		1,933		39	%		51	%
U.S.		489		534				1,022			319		421		431		448		740		1,619		27	%		38	%
International		127		149				277			52		70		86		106		122		314		114	%		127	%
Global Cholesterol: 1/		1,160		1,288				2,448			786		965		1,018		1,089		1,751		3,858		34	%		40	%
U.S.		897		958				1,854			634		784		820		852		1,419		3,091		22	%		31	%
International		263		330				594			152		181		198		237		332		767		83	%		79	%

1/ Substantially all sales of cholesterol products are not included in Schering-Plough’s net sales. Global franchise sales include sales under the Merck/Schering-Plough partnership, plus any sales that are not part of the partnership, such as Schering-Plough sales of cholesterol products in Latin America and Japan. In Japan, Schering-Plough co-markets Zetia with Bayer HealthCare. Zetia was launched in Japan in June 2007. In the second quarter of 2007 and 2006, sales in non-joint venture territories of the cholesterol franchise totaled $40 million and $7 million, respectively. For the first six months of 2007 and 2006, sales in non-joint venture territories of the cholesterol franchise totaled $51 million and $14 million, respectively.

The results of the operation of the joint venture are reflected in equity income. As a result, Schering-Plough’s gross margin and ratios of selling, general and administrative expenses and R&D expenses as a percentage of sales do not reflect the benefit of the impact of the cholesterol joint venture’s operating results.

Schering-Plough utilizes the equity method of accounting for the joint venture. The cholesterol agreements provide for the sharing of operating income based upon percentages that vary by product, sales level and country. In the U.S. market, Schering-Plough receives a greater share of profits on the first $300 million of annual ZETIA sales. Above $300 million of annual ZETIA sales, the companies share profits equally. Schering-Plough’s allocation of joint venture income is increased by milestones earned. Further, either partner’s share of the joint venture’s operating income is subject to a reduction if the partner fails to perform a specified minimum number of physician details in a particular country. The partners agree annually to the minimum number of physician details by country.

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 3

SCHERING-PLOUGH CORPORATION
PRESCRIPTION PHARMACEUTICAL SALES — KEY PRODUCT NET SALES
(Dollars in Millions)

	Global Prescription Pharma							U.S.							International
	2007		2006					2007		2006					2007		2006
	2nd		2nd		2nd Qtr			2nd		2nd		2nd Qtr			2nd		2nd		2nd Qtr
	Qtr.		Qtr.		vs			Qtr.		Qtr.		vs			Qtr.		Qtr.		vs
	$		$		2nd Qtr			$		$		2nd Qtr			$		$		2nd Qtr
Prescription Pharm:		2,520		2,230		13	%		771		718		7	%		1,749		1,512		16	%
Remicade		394		307		28	%		—		—		—			394		307		28	%
Nasonex		295		242		22	%		175		144		22	%		120		98		22	%
Clarinex / Aerius		250		226		11	%		106		97		9	%		144		129		12	%
PegIntron		234		226		3	%		46		57		(19	%)		188		169		11	%
Temodar		216		171		26	%		79		72		10	%		137		99		38	%
Claritin Rx		102		104		(1	%)		—		—		—			102		104		(1	%)
Integrilin		78		82		(5	%)		73		78		(6	%)		5		4		8	%
Avelox		75		58		30	%		75		58		30	%		—		—		—
Rebetol		74		86		(14	%)		1		2		(56	%)		73		84		(13	%)
Caelyx		65		53		23	%		—		—		—			65		53		23	%
Proventil / Albuterol cfc		61		63		(4	%)		61		63		(4	%)		—		—		—
Intron A		55		64		(13	%)		28		33		(15	%)		27		31		(12	%)
Subutex / Suboxone		52		53		(2	%)		—		—		—			52		53		(2	%)
Elocon		43		38		12	%		—		1		N/M			43		37		16	%
Asmanex		42		20		108	%		39		18		119	%		3		2		16	%
Foradil		26		23		10	%		25		22		10	%		1		1		—
Noxafil		20		3		N/M			7		—		N/M			13		3		N/M

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 4

SCHERING-PLOUGH CORPORATION
GLOBAL PRESCRIPTION PHARMACEUTICAL SALES — KEY PRODUCT NET SALES
(Dollars in Millions)

	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.
Global Prescription Pharm:		2,398		2,520				4,918			2,032		2,230		2,087		2,211		4,263		8,561		13	%		15	%
Remicade		373		394				767			278		307		317		337		585		1,240		28	%		31	%
Nasonex		284		295				579			229		242		221		253		471		944		22	%		23	%
Clarinex / Aerius		204		250				455			160		226		171		164		386		722		11	%		18	%
PegIntron		217		234				451			196		226		206		208		423		837		3	%		7	%
Temodar		196		216				412			163		171		179		189		334		703		26	%		23	%
Claritin Rx		112		102				214			101		104		74		78		205		356		(1	%)		5	%
Integrilin		84		78				163			80		82		82		85		162		329		(5	%)		—
Avelox		115		75				191			80		58		63		103		138		304		30	%		38	%
Rebetol		71		74				146			78		86		72		75		164		311		(14	%)		(11	%)
Caelyx		62		65				127			51		53		52		49		104		206		23	%		22	%
Proventil / Albuterol Cfc		53		61				114			41		63		45		55		104		203		(4	%)		10	%
Intron A		60		55				115			60		64		57		57		124		237		(13	%)		(7	%)
Subutex / Suboxone		56		52				108			48		53		51		51		101		203		(2	%)		7	%
Elocon		36		43				79			34		38		36		33		72		141		12	%		8	%
Asmanex		43		42				85			20		20		28		36		40		103		108	%		112	%
Foradil		26		26				52			21		23		22		28		44		94		10	%		17	%
Noxafil		16		20				36			2		3		6		10		4		19		N/M			N/M

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 5

SCHERING-PLOUGH CORPORATION
U.S. PHARMACEUTICAL SALES — KEY PRODUCT NET SALES
(Dollars in Millions)

	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.
Total U.S. Pharm:		802		771				1,573			656		718		733		800		1,375		2,908		7	%		14	%
Nasonex		177		175				352			144		144		153		171		288		611		22	%		22	%
Clarinex / Aerius		91		106				197			70		97		98		94		167		358		9	%		18	%
PegIntron		49		46				95			43		57		51		49		100		201		(19	%)		(5	%)
Temodar		74		79				154			67		72		72		74		140		286		10	%		10	%
Integrilin		80		73				153			76		78		78		81		154		312		(6	%)		—
Avelox		115		75				191			80		58		63		103		138		304		30	%		38	%
Proventil / Albuterol Cfc		53		61				114			41		63		45		55		104		203		(4	%)		10	%
Intron A		31		28				59			30		33		28		29		63		120		(15	%)		(5	%)
Elocon		—		—				—			—		1		1		1		2		3		N/M			N/M
Asmanex		40		39				80			18		18		26		33		36		94		119	%		123	%
Foradil		25		25				50			20		22		22		27		42		91		10	%		18	%
Noxafil		6		7				13			—		—		2		3		—		4		N/M			N/M

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 6

SCHERING-PLOUGH CORPORATION
INTERNATIONAL PHARMACEUTICAL SALES — KEY PRODUCT NET SALES
(Dollars in Millions)

	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.
Total International Pharm:		1,596		1,749				3,345			1,376		1,512		1,354		1,411		2,888		5,653		16	%		16	%
Remicade		373		394				767			278		307		317		337		585		1,240		28	%		31	%
Nasonex		107		120				227			85		98		68		82		183		333		22	%		24	%
Clarinex / Aerius		113		144				258			90		129		73		70		219		364		12	%		18	%
PegIntron		168		188				356			153		169		155		159		323		636		11	%		10	%
Temodar		122		137				258			96		99		107		115		194		417		38	%		33	%
Claritin Rx		112		102				214			101		104		74		78		205		356		(1	%)		5	%
Integrilin		4		5				10			4		4		4		4		8		17		8	%		11	%
Rebetol		71		73				144			76		84		72		73		161		306		(13	%)		(10	%)
Caelyx		62		65				127			51		53		52		49		104		206		23	%		22	%
Intron A		29		27				56			30		31		29		28		61		117		(12	%)		(8	%)
Subutex / Suboxone		56		52				108			48		53		51		51		101		203		(2	%)		7	%
Elocon		36		43				79			34		37		35		32		70		138		16	%		12	%
Asmanex		3		3				5			2		2		2		3		4		9		16	%		19	%
Noxafil		10		13				23			2		3		4		7		4		15		N/M			N/M

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 7

SCHERING-PLOUGH CORPORATION
GLOBAL CONSUMER HEALTH CARE
NET SALES ANALYSIS
(Dollars in Millions)

	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.
Consumer Health Care:		345		394				739			311		349		259		205		659		1,123		13	%		12	%
OTC:		177		182				359			153		149		138		118		302		558		22	%		19	%
OTC Claritin		127		137				264			111		111		95		72		222		390		23	%		19	%
Other OTC		50		45				95			42		38		43		46		80		168		20	%		19	%
Foot Care		78		102				180			83		96		92		73		179		343		7	%		1	%
Sun Care		90		110				200			75		104		29		14		178		222		6	%		12	%

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 8

SCHERING-PLOUGH CORPORATION
CONSOLIDATED OPERATIONS DATA
(Dollars in Millions)
(Unaudited)

	2007												2006
	1st			2nd			3rd	4th	6			Full	1st			2nd			3rd			4th			6			Full
	Qtr.			Qtr.			Qtr.	Qtr.	Mos.			Year	Qtr.			Qtr.			Qtr.			Qtr.			Mos.			Year
	$			$			$	$	$			$	$			$			$			$			$			$
Geographic net sales
U.S.		1,179			1,195					2,374				999			1,103			1,047			1,043			2,102			4,192
Europe and Canada		1,215			1,343					2,558				1,046			1,206			1,044			1,107			2,252			4,403
Latin America		311			327					638				260			248			233			249			508			990
Asia Pacific		270			313					583				246			261			250			251			507			1,009
Consolidated net sales		2,975			3,178					6,153				2,551			2,818			2,574			2,650			5,369			10,594
	2007												2006
	1st			2nd			3rd	4th	6			Full	1st			2nd			3rd			4th			6			Full
	Qtr.			Qtr.			Qtr.	Qtr.	Mos.			Year	Qtr.			Qtr.			Qtr.			Qtr.			Mos.			Year
	$			$			$	$	$			$	$			$			$			$			$			$
Other income, net
Interest income		(82	)		(86	)				(167	)			(68	)		(69	)		(77	)		(83	)		(137	)		(297	)
Interest expense		37			39					76				46			45			40			41			91			172
(Gain)/loss on fair value of foreign currency option		(3	)		35					31				—			—			—			—						—
Foreign exchange (gains)/losses		—			(3	)				(2	)			—			5			—			(4	)		6			2
Other (income)/expense		—			(1	)				—				(12	)		—			—			—			(12	)		(12	)
Total — Other income, net		(48	)		(16	)				(62	)			(34	)		(19	)		(37	)		(46	)		(52	)		(135	)

All figures rounded. Totals may not add due to rounding.

Alex Kelly	908-298-7450
Robyn Brown	908-298-7417

Page 9